Table 3. Relationship between genetic abnormalities and patient survival for intensively treated patients.
|
Myeloma IX
n=511 |
Myeloma XI
n=598 |
Combined
n=1109 |
Heterogeneity | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | P-value | |
| (a) Progression-free survival | |||||||
| t(4;14) | 1.96 (1.49–2.59) | 1.80 × 10−6 | 2.03 (1.56–2.64) | 2.18 × 10−7 | 2.00 (1.65–2.42) | 1.85 × 10−12 | 0.88 |
| t(14;16) | 1.60 (0.96–2.69) | 0.0729 | 2.03 (1.19–3.47) | 0.0099 | 1.80 (1.23–2.60) | 0.0021 | 0.54 |
| t(14;20) | 0.96 (0.46–2.03) | 0.9192 | 0.64 (0.09–4.54) | 0.6524 | 0.91 (0.45–1.84) | 0.7987 | 0.70 |
| Adverse translocations | 1.81 (1.42–2.31) | 1.79 × 10−6 | 2.09 (1.62–2.68) | 8.88 × 10−9 | 1.94 (1.63–2.31) | 1.07 × 10−13 | 0.42 |
| Del(17p) | 1.81 (1.30–2.51) | 0.0004 | 1.81 (1.29–2.52) | 0.0005 | 1.81 (1.43–2.28) | 7.25 × 10−7 | 1.00 |
| Gain(1q) | 1.48 (1.22–1.80) | 7.44 × 10−5 | 1.65 (1.31–2.07) | 2.03 × 10−5 | 1.55 (1.34–1.80) | 7.59 × 10−9 | 0.49 |
| Del(1p32) | 1.05 (0.76–1.47) | 0.7556 | 1.48 (1.04–2.09) | 0.0286 | 1.23 (0.97–1.57) | 0.0833 | 0.17 |
| ISS II | 1.34 (1.01–1.77) | 0.0409 | 1.48 (1.11–1.99) | 0.0085 | 1.40 (1.15–1.72) | 0.0009 | 0.61 |
| ISS III | 1.43 (1.07–1.91) | 0.0168 | 2.20 (1.61–3.01) | 7.88 × 10−7 | 1.74 (1.40–2.16) | 3.11 × 10−7 | 0.04 |
| 1 Adverse lesion | 1.50 (1.21–1.85) | 0.0002 | 1.49 (1.15–1.93) | 0.0024 | 1.50 (1.27–1.76) | 1.36 × 10−6 | 0.99 |
| ‘Double hit’ >1 adverse lesion | 2.31 (1.75–3.05) | 3.67 × 10−14 | 3.00 (2.24–4.02) | 2.17 × 10−13 | 2.61 (2.13–3.20) | 1.07 × 10−20 | 0.21 |
| Intermediate risk-ISS | 1.47 (1.16–1.86) | 0.0015 | 1.87 (1.45–2.41) | 1.45 × 10−6 | 1.64 (1.38–1.95) | 2.10 × 10−8 | 0.17 |
| ‘Double hit’-ISS | 2.78 (1.96–3.95) | 9.85 × 10−9 | 3.42 (2.47–4.75) | 1.92 × 10−13 | 3.11 (2.45–3.95) | 1.59 × 10−20 | 0.40 |
|
Myeloma IX
n=511 |
Myeloma XI
n=598 |
Combined
n=1109 |
Heterogeneity | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | P-value | |
| (b) OS | |||||||
| t(4;14) | 1.74 (1.26–2.41) | 0.0008 | 2.09 (1.41–3.07) | 0.0002 | 1.87 (1.46–2.40) | 7.62 × 10−7 | 0.49 |
| t(14;16) | 1.51 (0.79–2.84) | 0.2059 | 2.31 (1.13–4.73) | 0.0218 | 1.82 (1.13–2.92) | 0.01359 | 0.38 |
| t(14;20) | 1.44 (0.59–3.49) | 0.4181 | 1.91 (0.26–13.70) | 0.5219 | 1.51 (0.67–3.39) | 0.3169 | 0.80 |
| Adverse translocations | 1.74 (1.30–2.33) | 0.0002 | 2.30 (1.60–3.31) | 6.99 × 10−6 | 1.94 (1.55–2.43) | 9.91 × 10−9 | 0.24 |
| Del(17p) | 2.31 (1.61–3.31) | 5.87 × 10−6 | 3.19 (2.10–4.85) | 5.74 × 10−8 | 2.65 (2.01–3.48) | 3.04 × 10−12 | 0.25 |
| Gain(1q) | 1.79 (1.40–2.27) | 2.33 × 10−6 | 1.72 (1.22–2.43) | 0.0020 | 1.77 (1.45–2.15) | 1.65 × 10−8 | 0.86 |
| Del(1p32) | 1.84 (1.28–2.64) | 0.0010 | 1.99 (1.25–3.18) | 0.0037 | 1.89 (1.42–2.52) | 1.23 × 10−5 | 0.78 |
| ISS II | 1.96 (1.32–2.90) | 0.0008 | 1.88 (1.14–3.11) | 0.0140 | 1.92 (1.41–2.63) | 3.27 × 10−5 | 0.90 |
| ISS III | 2.56 (1.72–3.81) | 3.59 × 10−6 | 3.22 (1.94–5.35) | 6.56 × 10−6 | 2.79 (2.04–3.81) | 1.30 × 10−10 | 0.49 |
| 1 Adverse lesion | 1.73 (1.32–2.26) | 6.91 × 10−5 | 1.62 (1.08–2.44) | 0.0207 | 1.69 (1.35–2.12) | 4.30 × 10−6 | 0.79 |
| ‘Double hit’ >1 Adverse lesion | 2.84 (2.05–3.94) | 3.70 × 10−10 | 3.88 (2.55–5.92) | 2.98 × 10−10 | 3.19 (2.47–4.14) | 1.23 × 10−18 | 0.25 |
| Intermediate risk-ISS | 2.36 (1.71–3.25) | 1.44 × 10−7 | 2.26 (1.49–3.43) | 0.0001 | 2.32 (1.80–3.00) | 7.15 × 10−11 | 0.87 |
| ‘Double hit’-ISS | 4.51 (2.97–6.83) | 1.26 × 10−12 | 5.18 (3.24–8.27) | 5.78 × 10−12 | 4.79 (3.51–6.54) | 5.10 × 10−23 | 0.66 |
Abbreviations: CI, confidence interval; HR, hazard ratio; ISS, International Staging System; OS, overall survival.